European Patent Office Maintains FibroGen Patent Relating to Hypoxia-Inducible Factor (HIF) Prolyl Hydroxylase Inhibitor Technology

SAN FRANCISCO, June 05, 2017 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, announced today that a FibroGen European patent relating to the therapeutic use of certain small molecule inhibitors of hypoxia-inducible factor (HIF) prolyl hydroxylase was maintained by the European Patent Office.

Last week, the Opposition Division of the European Patent Office confirmed the patentability of claims in FibroGen’s European Patent Number 2322153, entitled “Use Of HIF Alpha Stabilizers For Enhancing Erythropoiesis.” The upheld claims relate to increasing serum iron in the treatment of iron deficiency and the use of structural mimetics of 2-oxoglutarate …

Source: Original Article